Novartis AG (NVS)
Novartis AG (NVS) is a healthcare company (drug manufacturers - general) based in Switzerland. The share price is $159.77, down 0.27% on the day, which values the company at $301.75B. Price as of 17 Nov 2026, 17:33 UTC, from Yahoo Finance.
Key facts
- Share price
- $159.77−0.27% today
- Market value
- $301.75B
- P/E ratio
- 30.5×last 12 months
- Forward P/E
- 16.1×
- Dividend yield
- 2.91%
- Funk Score
- 67/100
- Against its own history
- Well above its usual priceusual price $119.27
- 200-week average
- $117.5936% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Novartis AG in more detail
NVS trades at 30.5× its last twelve months' earnings, 16.1× next year's expected earnings, 5.3× sales. Measured against its own history, the price is 34% above what its usual multiples would imply ($119.27) — well above its usual price. It sits 36% above its 200-week average of $117.59.
Its Funk Score is 67 out of 100 (financial strength 7.3, profitability 9.7, growth 7.7, value 2.0, each out of 10).
In its favour: Strong Piotroski score; Share count keeps falling.
13 of the superinvestors tracked here hold NVS, including Tweedy, Browne team (0.8% of the portfolio), Ken Fisher (0.7% of the portfolio), Primecap team (0.6% of the portfolio).
Superinvestors holding NVS
13 of the investors tracked here report a position in their latest 13F filing.
- Tweedy, Browne team Tweedy, Browne Company0.80% of portfolio · $9.8M · trimmed · Q3 2026
- Ken Fisher Fisher Investments0.69% of portfolio · $2.4B · added · Q3 2026
- Primecap team Primecap Management0.58% of portfolio · $938.9M · trimmed · Q3 2026
- Brandon Haley Holocene Advisors0.37% of portfolio · $162.6M · new · Q2 2026
- Larry Robbins Glenview Capital Management0.27% of portfolio · $13.6M · new · Q2 2026
- Thomas Kahn Kahn Brothers0.27% of portfolio · $1.6M · trimmed · Q3 2026
- Andrew Spokes Farallon Capital Management0.19% of portfolio · $36.4M · trimmed · Q3 2026
- Charles Brandes (founder) Brandes Investment Partners0.18% of portfolio · $26.7M · trimmed · Q3 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)0.09% of portfolio · $40.2M · added · Q3 2026
- Dodge & Cox team Dodge & Cox0.06% of portfolio · $104.8M · trimmed · Q3 2026
- Lee Ainslie Maverick Capital0.04% of portfolio · $4.4M · added · Q2 2026
- Murray Stahl Horizon Kinetics0.02% of portfolio · $1.4M · trimmed · Q3 2026
- Rajiv Jain GQG Partners0.01% of portfolio · $6.7M · trimmed · Q3 2026
Health Care companies of similar size
- Eli LillyLLY
- Johnson & JohnsonJNJ
- AbbVieABBV
- Merck & CoMRK
- UnitedHealth GroupUNH
- AstraZenecaAZN
- Thermo Fisher ScientificTMO
- AmgenAMGN
- Gilead SciencesGILD
- Abbott LaboratoriesABT
- Novo NordiskNVO
- PfizerPFE
Side by side:NVS vs AZN (Novartis AG vs AstraZeneca)NVS vs UNH (Novartis AG vs UnitedHealth Group)NVS vs MRK (Novartis AG vs Merck & Co)NVS vs TMO (Novartis AG vs Thermo Fisher Scientific)NVS vs ABBV (Novartis AG vs AbbVie)
All health care companies by market valueLargest companies in SwitzerlandAll stocks A–Z
Novartis AG (NVS): questions and answers
What is NVS's P/E ratio?
Novartis AG trades at 30.5× its last twelve months' earnings and 16.1× next year's expected earnings. At its fiscal year-ends over the past 4 years the P/E ranged from 14.2× to 28.6×, with a median of 17.9×.
What is NVS's PEG ratio?
Novartis AG's PEG ratio is 3.82 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Novartis AG's market cap?
Novartis AG is valued at $301.75B at a share price of $159.77.
Is NVS overvalued or undervalued?
Against its own history, NVS is well above its usual price: the price is 34% above the $119.27 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is NVS above its 200-week moving average?
Yes. NVS is 35.9% above its 200-week average of $117.59. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Novartis AG growing?
Over the last three fiscal years Novartis AG's revenue grew 9.3% a year and its earnings per share 31.1% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Novartis AG (NVS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NVS
Underlying data: Yahoo Finance; company filings with the SEC.